Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 11/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
| ▸ | SDHB | P21912 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23168775 | 0.90 | MAPT (0.43) | NPBWR1MCHR1MAPTTP53LMNA | |
| SCHEMBL23168654 | 0.90 | MAPT (0.51) | NPBWR1MAPTTP53LMNACMA1 | |
| SCHEMBL29821419 | 0.90 | MAPT (0.51) | NPBWR1MAPTTP53LMNACMA1 | |
| SCHEMBL23168940 | 0.88 | MAPT (0.40) | MAPTTP53LMNA | |
| SCHEMBL24820993 | 0.88 | MKNK1 (0.42) | NPBWR1MAPT | |
| SCHEMBL23168928 | 0.85 | THRB (0.38) | NPBWR1LMNA | |
| SCHEMBL23168951 | 0.85 | MAPT (0.40) | MAPT | |
| SCHEMBL23168745 | 0.85 | KLKB1 (0.40) | NPBWR1MCHR1CHRM5 | |
| SCHEMBL31356395 | 0.85 | MAPT (0.40) | MAPT | |
| SCHEMBL23168932 | 0.84 | NPBWR1 (0.43) | NPBWR1MCHR1MAPTTP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617769-B2 | Chemical compound as thyroid hormone beta receptor agonist and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| US-20220411400-A1 | CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-12-29 | — | — | US | disclosed |
| US-20220411400-A1 | CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-12-29 | — | — | US | disclosed |
| EP-4036090-A1 | CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2022-08-03 | — | — | EP | disclosed |
| WO-2021057791-A1 | CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | 广东东阳光药业有限公司 | 2021-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411400-A1 | CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | THRB, TSHR, THRA | NPBWR1 336/4885MCHR1 251/4885MAPT 1873/4885 |
| US-12617769-B2 | Chemical compound as thyroid hormone beta receptor agonist and use thereof | THRB, TSHR, THRA | NPBWR1 267/4885MCHR1 223/4885MAPT 2264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.